Immunotherapy has revolutionized the management of microsatellite instability-high (MSI-H) and mismatch-repair-deficient (dMMR) metastatic colorectal cancer. However, significant unmet needs remain. Stay current with the latest clinical evidence and expert perspectives to refine your treatment approach.

Watch our on-demand webinar featuring Dr. Eric Chen and Dr. Mustapha Tehfe as they navigate recent advances and best practices in patient management.

Enhance your knowledge by downloading our CheckMate-8HW infographic, which provides a detailed analysis of dual-checkpoint inhibition (nivolumab + ipilimumab) versus standard care. Learn to optimize first-line strategies and effectively manage immune-mediated adverse events for better patient outcomes.